She believes that algorithmic bias in clinical trials is the single biggest problem facing the pharma industry, one which is driving the health equity gap, and an issue that there is an inertia to ...

The primary value of placebo controls in clinical trials is the minimization of bias.

Bias against female subjects starts to "creep ... Medical School found that women accounted for about 40% of clinical trials for three diseases that most affect women despite representing 51% ...

COVID-19 provided a stark example of this bias. Despite clear evidence that men and women had different infection rates, drug responses, and mortality risks, only 4% of clinical trials actively ...

Recent innovations in evidence based medicine methods, in particular instruments assessing risk of bias in randomised trials, have focused on methodological rigour at the expense of simplicity and ...

Inclusion of female and Hispanic/Latino patients has increased over time, but most trials of metabolic dysfunction-associated ...

From your seat belt to your medicines, many aspects of our society have been designed with the average male in mind — often ...

Fortunately, the bias of clinical testing may be changing. Almost half of trial participants in America are now women (in the ...

a fellow in Clinical Informatics at Mass General Brigham and a fellow in Cardiovascular Medicine at Brigham and Women's ...